{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-054910","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.561889+00:00","generated_at":"2026-06-03T04:17:32.959871+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Immunome VP Finance/PAO Bob Lapetina resigns; Max Rosett named PAO effective May 10","bullets":["Bob Lapetina resigned as VP Finance, Corporate Controller and principal accounting officer effective May 10, 2024; departure not due to disagreement.","Max Rosett appointed principal accounting officer effective May 10, 2024; he currently serves as Interim CFO, EVP Operations since December 2023.","Rosett previously held roles at Morphimmune and Research Bridge Partners; no new material plan or contract entered in connection with appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-054910","json":"https://secwatch.observer/filing/0001104659-24-054910.json","markdown":"https://secwatch.observer/filing/0001104659-24-054910.md","text":"https://secwatch.observer/filing/0001104659-24-054910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924054910/0001104659-24-054910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924054910/tm2413152d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:17:32.959871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b9537832b","claim":"Max Rosett was appointed as principal accounting officer at Immunome Inc..","evidence_excerpt":"the Company’s board of directors appointed Max Rosett, in addition to his other titles, as the Company’s principal accounting officer effective immediately upon the effectiveness of Mr. Lapetina’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924054910/0001104659-24-054910-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"d25cbc01b4","claim":"Bob Lapetina departed as Vice President, Finance, Corporate Controller, and principal accounting officer at Immunome Inc..","evidence_excerpt":"Bob Lapetina notified Immunome, Inc. (the “Company”) that he will be resigning from his positions as the Company’s Vice President, Finance, Corporate Controller, and principal accounting officer to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924054910/0001104659-24-054910-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigning"},{"label":"Role","value":"Vice President, Finance, Corporate Controller, and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}